Plasma Protein Therapeutics Market Report

Global Plasma Protein Therapeutics Market Size

The global plasma protein therapeutics market size was valued at USD 33.75 billion in 2025. The plasma protein therapeutics market is estimated to grow to USD 73.13 billion by 2034 from USD 36.78 billion in 2026, growing at a CAGR of 8.97% during the forecast period.

The plasma protein therapeutics are biopharmaceuticals derived from human plasma, including immunoglobulins, albumin, and coagulation factors, which are essential for treating rare chronic conditions and acute trauma. These life-saving therapies rely on the fractionalization of donated blood to isolate specific proteins required for immune function, clotting, and volume expansion. According to the World Health Organization, only 58 countries worldwide have sufficient plasma collection capabilities to meet their domestic needs, amplifying a critical global supply imbalance. As per the Centers for Disease Control and Prevention, primary immunodeficiency affects approximately 1 in 1200 individuals in the United States by creating a consistent and non-discretionary demand for immunoglobulin replacements. As per the European Centre for Disease Prevention and Control, hemophilia A affects roughly 1 in 5000 male births, necessitating lifelong treatment with factor VIII concentrates. Furthermore, the American Association of Blood Banks reports that less than 3% of eligible donors actually donate plasma, constraining the raw material supply chain. These epidemiological realities underscore the irreplaceable nature of plasma derived medicines. The market operates under stringent regulatory oversight to ensure viral safety and product purity, driving continuous innovation in fractionation technologies and donor recruitment strategies to address the widening gap between clinical need and available therapeutic volumes.

MARKET DRIVERS

Rising Prevalence of Rare Chronic Immune and Bleeding Disorders

The escalating prevalence of rare chronic immune and bleeding disorders that is escalating the growth of the plasma protein therapeutics market. According to the National Organization for Rare Disorders, over 30 million Americans suffer from one of the 7000 identified rare diseases, many of which require plasma derived therapies for management. This statistical increase directly translates to higher prescription volumes for intravenous and subcutaneous immunoglobulins. These figures demonstrate a direct correlation between patient identification and market growth. As healthcare systems improve screening programs, more patients enter treatment pipelines, sustaining long term demand. The chronic nature of these conditions ensures recurring revenue streams for manufacturers, as patients require lifelong therapy. The expanding diagnosed patient pool drives sustained investment in production capacity and distribution networks to meet the critical medical needs of these vulnerable populations.

Aging Global Population and Increased Surgical Interventions

The aging global population and the corresponding rise in surgical interventions profoundly by driving demand for albumin and coagulation factors that is fuelling the growth of the plasma protein therapeutics market. According to the United Nations Department of Economic and Social Affairs, the number of people aged 65 and older is projected to double to 1.5 billion by 2050, significantly increasing the burden of age-related health issues. Older adults are more prone to trauma, liver disease, and complex surgeries, all of which often require human albumin for volume resuscitation and shock management. As per data, the use of albumin in care units has remained stable or increased despite the availability of synthetic alternatives, due to its proven efficacy in specific clinical scenarios. The growing frequency of orthopedic and cardiovascular surgeries in elderly populations further amplifies this demand.

MARKET RESTRAINTS

Stringent Regulatory Requirements and Safety Concerns

The stringent regulatory requirements and persistent safety concerns by increasing compliance costs and limiting supply flexibility is degrading the growth of the plasma protein therapeutics market. The plasma derived medicinal products must undergo rigorous viral validation and traceability checks, with manufacturing facilities subject to frequent inspections to ensure pathogen safety. The complexity of these regulations means that bringing a new fractionation facility online can take up to five years, delaying capacity expansion. The Food and Drug Administration states that any deviation in donor screening or processing protocols can lead to immediate product recalls and facility shutdowns, creating high operational risks. These strict standards discourage new entrants and consolidate the market among a few established players who can afford the compliance burden. Additionally, historical incidents of viral transmission have left a legacy of caution, prompting regulators to maintain extremely conservative approval pathways.

Limited Donor Base and Collection Constraints

The limited donor base and logistical constraints in plasma collection is also limiting the growth of the plasma protein therapeutics market. According to the World Health Organization, only 2% of the global population donates blood or plasma, despite the fact that approximately 100 million donations are needed annually to meet current therapeutic requirements. This stark disparity between supply and demand creates chronic shortages, particularly for specialized immunoglobulins. Unlike synthetic drugs, plasma proteins cannot be manufactured chemically, making the market entirely dependent on voluntary human donation. As per data, the average time required to collect one unit of plasma is 90 minutes, limiting throughput capacity. Weather events, pandemics, and economic shifts further disrupt collection schedules, leading to volatile inventory levels. This reliance on a finite and fluctuating human resource prevents manufacturers from scaling production linearly with demand, keeping prices high and restricting access in lower income markets.

MARKET OPPORTUNITIES

Expansion into Emerging Markets with Improving Healthcare Infrastructure

The expansion into emerging countries with improving healthcare infrastructure by unlocking vast untreated patient populations is solely to create new opportunities for the growth of the plasma protein therapeutics market. The diagnosis rate for hemophilia has increased by 25% in recent years, creating a new cohort of patients requiring factor concentrates. These statistics indicate a shifting landscape where previously underserved regions are becoming viable commercial markets. As per data, the prevalence of immunodeficiency disorders in Asia is comparable to Western nations, suggesting significant latent demand for immunoglobulins. Governments in these regions are increasingly including plasma derived therapies in national reimbursement lists, reducing financial barriers for patients. Manufacturers can establish local fractionation plants or partnerships to navigate regulatory hurdles and reduce import costs. By focusing on education and awareness campaigns, companies can accelerate diagnosis and treatment initiation.

Development of Subcutaneous Administration Formats

The development and adoption of subcutaneous administration formats by enhancing patient convenience and adherence is also to fuel the growth of the plasma protein therapeutics market. According to the Journal of Clinical Immunology, subcutaneous immunoglobulin therapy allows patients to administer treatment at home, reducing the need for frequent hospital visits and intravenous access complications. The patient satisfaction scores are 30% higher for subcutaneous formulations compared to traditional intravenous infusions, driving preference and loyalty. This shift improves quality of life and reduces overall healthcare system burdens associated with infusion center staffing and overhead. Manufacturers are investing in user friendly delivery devices such as auto injectors and pumps to further simplify the process. This innovation expands the addressable patient base to include those who struggle with venous access or have busy lifestyles. By prioritizing patient centric design, companies can differentiate their products and command premium pricing. The transition to home-based care aligns with broader healthcare trends toward decentralization, creating a robust opportunity for volume growth and long term patient retention in the plasma therapeutics sector.

MARKET CHALLENGES

High Production Costs and Pricing Pressure

The high production costs and increasing pricing pressure by compressing margins and limiting accessibility is a major challenge for the growth of the plasma protein therapeutics market. According to the Plasma Protein Therapeutics Association, the cost of collecting, testing, and fractionating one liter of plasma exceeds 100 dollars, before accounting for distribution and marketing expenses. This high baseline cost makes plasma derived therapies inherently expensive compared to small molecule drugs. The reimbursement rates for certain plasma products have remained flat or decreased in real terms, while input costs continue to rise due to inflation and labor shortages. These financial dynamics force manufacturers to raise prices, which attracts scrutiny from payers and policymakers. Insurance providers are increasingly demanding evidence of cost effectiveness, delaying approvals and limiting patient access. Small biotech firms struggle to compete with established giants who benefit from economies of scale.

Competition from Recombinant and Synthetic Alternatives

The competition from recombinant and synthetic alternatives by eroding share in key therapeutic categories is also to decline the growth of the plasma protein therapeutics market. According to the World Federation of Hemophilia, the use of recombinant factor VIII and IX has surpassed plasma derived factors in many developed countries due to perceived safety advantages and consistent supply. Biotechnology advancements have enabled the production of high purity clotting factors without human plasma, eliminating the risk of human pathogen transmission entirely. As per data, several companies are developing recombinant albumin and immunoglobulin mimetics, threatening to disrupt traditional plasma fractions. While plasma derived products retain advantages in certain indications, the trend toward bioengineered solutions intensifies pricing competition and reduces growth potential. Manufacturers must continuously demonstrate the unique clinical benefits of plasma proteins, such as the presence of multiple protective antibodies, to justify their use.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type Insights

The albumin segment held a dominant share of the plasma protein therapeutics market in 2025 due to its indispensable role in care, trauma management, and major surgical interventions. Its unique ability to maintain oncotic pressure makes it superior to synthetic colloids in preventing edema and supporting organ perfusion during shock states. The World Health Organization lists albumin as an essential medicine for treating severe burns and liver cirrhosis, conditions that require long term management and frequent dosing. These clinical indications ensure a consistent and high volume demand across hospital settings globally. As per data, the usage of albumin in patients with sepsis has remained stable despite the availability of cheaper alternatives, driven by evidence showing improved survival rates in specific subgroups. This entrenched clinical preference sustains albumin as the highest revenue generating segment. Furthermore, the aging population increases the incidence of chronic liver disease and hypoalbuminemia, further driving prescription rates. The broad applicability of albumin across diverse medical specialties, from nephrology to oncology, ensures that it remains the backbone of the plasma protein market, unaffected by niche therapeutic trends.

The coagulation segment is expected to grow at an anticipated CAGR of 14.2% during the forecast period with the rising diagnosis rates of hemophilia and other bleeding disorders. According to the World Federation of Hemophilia, the global registered population of people with hemophilia has increased to over 400000, with diagnosis rates improving by 15% in developing nations due to better screening programs. Early detection leads to immediate initiation of prophylactic therapy, which requires regular infusions of factor VIII or IX concentrates. The Centers for Disease Control and Prevention states that comprehensive care centers in the United States have expanded access to genetic testing, identifying mild cases that previously went untreated. These statistics directly correlate with increased consumption of coagulation factors. As per data, the shift toward prophylactic treatment rather than on demand therapy has doubled the annual usage per patient, significantly boosting market growth. This change in clinical practice transforms hemophilia from an acute condition into a managed chronic disease, ensuring recurring revenue for manufacturers. The growing awareness among healthcare providers and patients about the benefits of early intervention further accelerates adoption.

By Application Insights

The primary immunodeficiency disorder segment held a significant share of the Plasma Protein Therapeutics Market in 2025 due to the lifelong dependency of patients on immunoglobulin replacement therapy. Once diagnosed, patients require regular infusions of intravenous or subcutaneous immunoglobulins to prevent recurrent infections and maintain immune function. The World Allergy Organization states that the standard of care involves monthly or weekly dosing, creating a predictable and sustained demand for plasma derived immunoglobulins. These statistics underscore the chronic nature of the condition and its direct impact on product consumption. As per data from clinical studies, early initiation of immunoglobulin therapy significantly reduces hospitalizations and antibiotic use, reinforcing its clinical necessity. Healthcare systems prioritize funding for these treatments due to their cost effectiveness in preventing severe complications. The established treatment protocols and clear clinical guidelines ensure that primary immunodeficiency remains the largest application area.

The secondary immunodeficiency segment is likely to grow at a fastest CAGR of 14.2% from 2026 to 2034 with the increasing prevalence of cancer and autoimmune diseases that compromise immune function. According to the International Agency for Research on Cancer, global cancer incidence is projected to rise by 50% by 2040, with many chemotherapy regimens causing significant immune suppression. Patients undergoing hematopoietic stem cell transplantation or receiving monoclonal antibody therapies often develop secondary hypogammaglobulinemia, requiring immunoglobulin supplementation. The expanding indication base for plasma proteins beyond primary genetic disorders. As per data, the use of immunoglobulins in oncology support care has increased by 12% annually, reflecting broader clinical acceptance. The aging population also contributes to higher rates of autoimmune conditions and malignancies, further fueling demand.

REGIONAL ANALYSIS

North America Plasma Protein Therapeutics Market Analysis

North America was the largest contributor in the Plasma Protein Therapeutics Market by accounting for 45.3% of share in 2025 due to high healthcare spending and advanced diagnostic capabilities. According to the study, the United States collects over 15 million liters of plasma annually, serving as a major global supplier for fractionation. The presence of leading manufacturers and a well established reimbursement framework support robust market growth. The Centers for Disease Control and Prevention states that diagnosis rates for primary immunodeficiency are highest in North America, driving strong demand for immunoglobulins. Additionally, the high prevalence of lifestyle related diseases and an aging population increase the need for albumin and coagulation factors. As per data from IQVIA, the region leads in the adoption of subcutaneous immunoglobulin therapies, reflecting patient preference for home based care. Regulatory clarity from the Food and Drug Administration ensures a steady pipeline of new products.

Europe Plasma Protein Therapeutics Market Analysis

Europe plasma protein therapeutics market was ranked second by holding 22.1% of share in 2025 with the strong public healthcare systems and emphasis on safety. The strict viral safety standards govern the production and distribution of plasma products by ensuring high quality but limiting speed to market. The European Federation of Immunodeficiencies reports that diagnosis and treatment rates vary significantly between Western and Eastern European countries, creating uneven growth patterns. Germany and France are key countries due to their large populations and advanced medical infrastructure. As per data, the shift toward recombinant factors in hemophilia treatment is more pronounced in Europe than in other regions, impacting plasma derived factor sales. However, demand for immunoglobulins remains strong due to aging demographics. Government initiatives to harmonize plasma collection and fractionation across borders aim to improve self-sufficiency.

Asia-Pacific Plasma Protein Therapeutics Market Analysis

Asia-Pacific plasma protein therapeutics market growth is anticipated to grow with the improving healthcare infrastructure and rising awareness of rare diseases. The region’s large population base offers immense potential for expansion, particularly in India and Southeast Asia. The diagnosis rates are improving, uncovering a significant untreated patient population. Economic growth enables greater access to advanced therapies, with insurance coverage expanding in countries like Japan and South Korea. As per data from local health ministries, the burden of infectious diseases and trauma drives high demand for albumin and immunoglobulins. Cultural barriers to donation are gradually being addressed through public education campaigns. The combination of rising disposable income, government support, and unmet medical needs positions Asia-Pacific as the primary driver of future global market growth.

Latin America Plasma Protein Therapeutics Market Analysis

Latin America plasma protein therapeutics market growth is likely to grow with the fragmented healthcare systems and varying levels of access. The plasma collection activities are concentrated in Brazil and Mexico, which serve as regional hubs for fractionation and distribution. The region faces challenges related to regulatory harmonization and funding constraints, limiting widespread adoption of expensive therapies. Many patients rely on patient assistance programs from manufacturers to access immunoglobulins. Economic volatility affects purchasing power, leading to fluctuations in demand. Governments are increasingly recognizing rare diseases as public health priorities, leading to incremental improvements in reimbursement policies.

The Middle East and Africa Plasma Protein Therapeutics Market Analysis

The Middle East and Africa plasma protein therapeutics market is likely to grow with the high prevalence of genetic disorders and increasing healthcare investment. Gulf Cooperation Council countries lead in adoption due to high healthcare spending and advanced medical facilities, while Sub Saharan Africa faces significant access barriers. The African Society for Laboratory Medicine states that limited diagnostic capacity hinders identification of patients, keeping the treated population small. However, international aid and partnerships are improving access to essential medicines. As per data from regional health ministries, investments in blood bank infrastructure are increasing, supporting local plasma collection efforts. The growing population and urbanization create underlying demand for trauma and critical care products like albumin.

COMPETITIVE LANDSCAPE

The competition in the Plasma Protein Therapeutics Market is characterized by intense rivalry among established multinational corporations and emerging niche brands seeking to capture market share. Large dairy conglomerates leverage their extensive distribution networks and brand recognition to dominate mainstream segments while specialized biotechnology firms focus on high potency supplements and personalized solutions. Regulatory compliance creates barriers to entry favoring players with robust scientific validation capabilities. Digital transformation has intensified competition, as online platforms enable direct to consumer models that bypass traditional retail channels. Collaborations with healthcare professionals enhance credibility and drive prescription based sales. Consumer loyalty is driven by perceived efficacy and brand trust making reputation management crucial.

KEY MARKET PLAYERS

Companies that are playing a dominating role in the global plasma protein therapeutics market in this report are

• Baxter
• CSL Behring
• Biotest
• China Biologics
• Grifols
• Kedrion
• Octapharma
• Shire Plc,
• Chengdu Inst.

Top Players in the Plasma Protein Therapeutics Market

CSL Limited

CSL Limited stands as a global leader in the plasma protein therapeutics sector, leveraging its extensive network of plasma collection centers to ensure a robust supply chain. The company specializes in producing immunoglobulins, albumin, and coagulation factors that treat rare and serious medical conditions. CSL actively invests in research and development to enhance viral safety technologies and improve product yields. The company also focuses on strategic acquisitions to broaden its portfolio and enter new therapeutic areas. By prioritizing operational excellence and innovation, CSL strengthens its position as a trusted provider of life saving therapies while maintaining high standards of quality and regulatory compliance across its global operations.

Grifols S.A.

Grifols S.A. plays a pivotal role in the plasma protein therapeutics market through its integrated business model that spans from plasma collection to finished product distribution. The company is renowned for its advanced fractionation technologies and diverse portfolio of alpha 1 proteinase inhibitors and immunoglobulins. Grifols emphasizes sustainability and digital transformation to optimize donor recruitment and patient care services. The company collaborates with healthcare providers to improve access to therapies for patients with rare diseases. By focusing on innovation and global expansion, Grifols enhances its competitive edge and reinforces its commitment to improving patient outcomes through high quality plasma derived medicines.

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited contributes significantly to the plasma protein therapeutics market following its acquisition of Shire, which expanded its biologics portfolio. The company offers a wide range of immunoglobulins and coagulation factors designed to address unmet medical needs in hematology and immunology. Recent strategies include integrating plasma operations into its broader biopharmaceutical framework to drive synergies and cost efficiencies. Takeda focuses on developing next generation therapies with improved half lives and administration routes. The company also engages in partnerships to enhance plasma collection capabilities in key markets.

Top Strategies Used by Key Market Participants

Key players in the Plasma Protein Therapeutics Market employ diverse strategies to maintain competitive advantage and drive growth. Product innovation remains a primary focus with companies investing heavily in research and development to create novel formulations that address specific health needs such as immune support and mental well being. Strategic partnerships and collaborations with academic institutions enable firms to validate product efficacy through rigorous clinical trials enhancing consumer trust and regulatory compliance. Expansion into digital health platforms allows brands to offer personalized nutrition advice and subscription services fostering long term customer loyalty and recurring revenue streams. Mergers and acquisitions facilitate access to new technologies and distribution networks by enabling rapid market penetration and portfolio diversification. Sustainability initiatives are increasingly central to corporate strategies with manufacturers adopting eco-friendly packaging and ethical sourcing practices to align with consumer values and regulatory requirements.

RECENT MARKET HAPPENINGS

• In January 2023, to offer breakthrough minor molecule protein degrader medications, Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical business, is pursuing targeted protein degradation (TPD). The Phase 1 trial of Kymera's lead program, KT-474 (SAR444656), showed fidelity of translation from healthy volunteers to patients, a favorable safety profile, and clinical impact in complex inflammatory diseases like hidradenitis suppurativa (HS) and atopic dermatitis.
• In August 2018, in the U.S., Grifols S.A. acquired 24 plasma donor centers, which have thrived in the company's position, and Biotest AG will operate these companies to improve shares.
• In March 2018, the first immunoglobulin therapy received approval from the food and drug administration (FDA) and was developed by CSL’s Hizentra. It is highly used to treat chronic inflammatory demyelinating polyneuropathy (CIDP).
• In June 2016, Baxalta was acquired by Shire Plc, which enhanced its shares and developed its product portfolio. The main aim is to create a strong pipeline for the treatment of varied diseases which rarely occur.

MARKET SEGMENTATION

This report on the global plasma protein therapeutics market has been segmented & sub-segmented based on type, application, and region.

By Type

• Albumin
• Coagulation Factors
• Alpha-1 proteinase inhibitor
• Others

By Application

• Hemophilia
• Primary Immunodeficiency Disorder
• Idiopathic Thrombocytopenic Purpura
• Secondary Immunodeficiency
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa